ES2179945T3 - Compuestos de tetralina con actividad de resistencia a multiples farmacos. - Google Patents

Compuestos de tetralina con actividad de resistencia a multiples farmacos.

Info

Publication number
ES2179945T3
ES2179945T3 ES96920255T ES96920255T ES2179945T3 ES 2179945 T3 ES2179945 T3 ES 2179945T3 ES 96920255 T ES96920255 T ES 96920255T ES 96920255 T ES96920255 T ES 96920255T ES 2179945 T3 ES2179945 T3 ES 2179945T3
Authority
ES
Spain
Prior art keywords
compounds
tetraline
multiple drugs
resistance activity
invention refers
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
ES96920255T
Other languages
English (en)
Inventor
Robert E Zelle
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Vertex Pharmaceuticals Inc
Original Assignee
Vertex Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Vertex Pharmaceuticals Inc filed Critical Vertex Pharmaceuticals Inc
Application granted granted Critical
Publication of ES2179945T3 publication Critical patent/ES2179945T3/es
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/24—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with substituted hydrocarbon radicals attached to ring carbon atoms
    • C07D213/28—Radicals substituted by singly-bound oxygen or sulphur atoms
    • C07D213/30—Oxygen atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C45/00—Preparation of compounds having >C = O groups bound only to carbon or hydrogen atoms; Preparation of chelates of such compounds
    • C07C45/45—Preparation of compounds having >C = O groups bound only to carbon or hydrogen atoms; Preparation of chelates of such compounds by condensation
    • C07C45/46—Friedel-Crafts reactions
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C45/00—Preparation of compounds having >C = O groups bound only to carbon or hydrogen atoms; Preparation of chelates of such compounds
    • C07C45/61—Preparation of compounds having >C = O groups bound only to carbon or hydrogen atoms; Preparation of chelates of such compounds by reactions not involving the formation of >C = O groups
    • C07C45/67—Preparation of compounds having >C = O groups bound only to carbon or hydrogen atoms; Preparation of chelates of such compounds by reactions not involving the formation of >C = O groups by isomerisation; by change of size of the carbon skeleton
    • C07C45/68—Preparation of compounds having >C = O groups bound only to carbon or hydrogen atoms; Preparation of chelates of such compounds by reactions not involving the formation of >C = O groups by isomerisation; by change of size of the carbon skeleton by increase in the number of carbon atoms
    • C07C45/70—Preparation of compounds having >C = O groups bound only to carbon or hydrogen atoms; Preparation of chelates of such compounds by reactions not involving the formation of >C = O groups by isomerisation; by change of size of the carbon skeleton by increase in the number of carbon atoms by reaction with functional groups containing oxygen only in singly bound form
    • C07C45/71—Preparation of compounds having >C = O groups bound only to carbon or hydrogen atoms; Preparation of chelates of such compounds by reactions not involving the formation of >C = O groups by isomerisation; by change of size of the carbon skeleton by increase in the number of carbon atoms by reaction with functional groups containing oxygen only in singly bound form being hydroxy groups
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C49/00—Ketones; Ketenes; Dimeric ketenes; Ketonic chelates
    • C07C49/587—Unsaturated compounds containing a keto groups being part of a ring
    • C07C49/753—Unsaturated compounds containing a keto groups being part of a ring containing ether groups, groups, groups, or groups
    • C07C49/755—Unsaturated compounds containing a keto groups being part of a ring containing ether groups, groups, groups, or groups a keto group being part of a condensed ring system with two or three rings, at least one ring being a six-membered aromatic ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C59/00—Compounds having carboxyl groups bound to acyclic carbon atoms and containing any of the groups OH, O—metal, —CHO, keto, ether, groups, groups, or groups
    • C07C59/40—Unsaturated compounds
    • C07C59/58—Unsaturated compounds containing ether groups, groups, groups, or groups
    • C07C59/64—Unsaturated compounds containing ether groups, groups, groups, or groups containing six-membered aromatic rings
    • C07C59/66—Unsaturated compounds containing ether groups, groups, groups, or groups containing six-membered aromatic rings the non-carboxylic part of the ether containing six-membered aromatic rings
    • C07C59/68—Unsaturated compounds containing ether groups, groups, groups, or groups containing six-membered aromatic rings the non-carboxylic part of the ether containing six-membered aromatic rings the oxygen atom of the ether group being bound to a non-condensed six-membered aromatic ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links

Abstract

LA PRESENTE INVENCION SE REFIERE A COMPUESTOS QUE PUEDEN MANTENER, AUMENTAR O RESTAURAR LA SENSIBILIDAD DE LAS CELULAS A AGENTES TERAPEUTICOS O PROFILACTICOS. ESTA INVENCION SE REFIERE TAMBIEN A COMPOSICIONES FARMACOLOGICAS QUE CONTIENEN ESTOS COMPUESTOS. LOS COMPUESTOS Y LAS COMPOSICIONES FARMACOLOGICAS DE ESTA INVENCION SON ESPECIALMENTE ADECUADOS PARA EL TRATAMIENTO DE CELULAS RESISTENTES A MULTIPLES FARMACOS, PARA LA PREVENCION DEL DESARROLLO DE RESISTENCIA A MULTIPLES FARMACOS Y PARA LA UTILIZACION EN PROCESOS CANCEROSOS RESISTENTES A MULTIPLES FARMACOS. ESTOS COMPUESTOS ESTAN REPRESENTADOS POR LA FORMULA GENERAL (I), EN LA QUE LOS DIFERENTES SUSTITUYENTES ESTAN DEFINIDOS EN LA DESCRIPCION.
ES96920255T 1995-05-19 1996-05-16 Compuestos de tetralina con actividad de resistencia a multiples farmacos. Expired - Lifetime ES2179945T3 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US08/444,567 US5726184A (en) 1995-05-19 1995-05-19 Tetralin compounds with improved MDR activity

Publications (1)

Publication Number Publication Date
ES2179945T3 true ES2179945T3 (es) 2003-02-01

Family

ID=23765456

Family Applications (1)

Application Number Title Priority Date Filing Date
ES96920255T Expired - Lifetime ES2179945T3 (es) 1995-05-19 1996-05-16 Compuestos de tetralina con actividad de resistencia a multiples farmacos.

Country Status (22)

Country Link
US (1) US5726184A (es)
EP (1) EP0839143B1 (es)
JP (1) JPH11505255A (es)
KR (1) KR19990014848A (es)
CN (1) CN1184475A (es)
AT (1) ATE221881T1 (es)
AU (1) AU705167B2 (es)
BR (1) BR9608789A (es)
CA (1) CA2219752A1 (es)
CZ (1) CZ364197A3 (es)
DE (1) DE69622871T2 (es)
DK (1) DK0839143T3 (es)
ES (1) ES2179945T3 (es)
HU (1) HUP9802679A3 (es)
IL (1) IL118269A0 (es)
NO (1) NO975198L (es)
NZ (1) NZ308789A (es)
PL (1) PL323490A1 (es)
PT (1) PT839143E (es)
SK (1) SK155497A3 (es)
WO (1) WO1996036630A1 (es)
ZA (1) ZA963959B (es)

Families Citing this family (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5798355A (en) * 1995-06-07 1998-08-25 Gpi Nil Holdings, Inc. Inhibitors of rotamase enzyme activity
US5859031A (en) * 1995-06-07 1999-01-12 Gpi Nil Holdings, Inc. Small molecule inhibitors of rotamase enzyme activity
US5696135A (en) * 1995-06-07 1997-12-09 Gpi Nil Holdings, Inc. Inhibitors of rotamase enzyme activity effective at stimulating neuronal growth
US5811434A (en) * 1996-11-13 1998-09-22 Vertex Pharmacueticals Incorporated Methods and compositions for stimulating neurite growth
US5935989A (en) * 1996-12-31 1999-08-10 Gpi Nil Holdings Inc. N-linked ureas and carbamates of heterocyclic thioesters
SK57899A3 (en) * 1996-12-31 2000-05-16 Guilford Pharm Inc N-linked ureas and carbamates of heterocyclic thioesters
US5846979A (en) 1997-02-28 1998-12-08 Gpi Nil Holdings, Inc. N-oxides of heterocyclic esters, amides, thioesters, and ketones
US5945441A (en) 1997-06-04 1999-08-31 Gpi Nil Holdings, Inc. Pyrrolidine carboxylate hair revitalizing agents
FR2781218B1 (fr) 1998-07-15 2001-09-07 Lafon Labor Compositions pharmaceutiques comprenant des 2-quinolones
US6218423B1 (en) 1998-08-14 2001-04-17 Gpi Nil Holdings, Inc. Pyrrolidine derivatives for vision and memory disorders
US6337340B1 (en) 1998-08-14 2002-01-08 Gpi Nil Holdings, Inc. Carboxylic acids and isosteres of heterocyclic ring compounds having multiple heteroatoms for vision and memory disorders
US6395758B1 (en) 1998-08-14 2002-05-28 Gpi Nil Holdings, Inc. Small molecule carbamates or ureas for vision and memory disorders
US6462072B1 (en) 1998-09-21 2002-10-08 Gpi Nil Holdings, Inc. Cyclic ester or amide derivatives
US6307049B1 (en) 1998-09-30 2001-10-23 The Procter & Gamble Co. Heterocyclic 2-substituted ketoamides
US6300341B1 (en) 1998-09-30 2001-10-09 The Procter & Gamble Co. 2-substituted heterocyclic sulfonamides
US6323215B1 (en) 1999-07-09 2001-11-27 Ortho-Mcneil Pharmaceutical, Inc. Neurotrophic tetrahydroisoquinolines and tetrahydrothienopyridines, and related compositions and methods
FR2797444B1 (fr) 1999-08-13 2003-02-07 Lafon Labor Compositions pharmaceutiques comprenant des 4-quinolones
MXPA03003401A (es) * 2000-10-16 2004-06-30 Neopharm Inc Formulacion liposomica de mitoxantrona.
US6693099B2 (en) 2000-10-17 2004-02-17 The Procter & Gamble Company Substituted piperazine compounds optionally containing a quinolyl moiety for treating multidrug resistance
US6376514B1 (en) 2000-10-17 2002-04-23 The Procter & Gamble Co. Substituted six-membered heterocyclic compounds useful for treating multidrug resistance and compositions and methods thereof
EP1404325A2 (en) * 2001-05-29 2004-04-07 Guilford Pharmaceuticals Inc. Method for treating nerve injury caused by surgery
EP1451856A2 (en) * 2001-11-07 2004-09-01 Pharmacia Corporation Methods of promoting uptake and nuclear accumulation of polyamides in eukaryotic cells
WO2005007162A1 (en) * 2003-07-10 2005-01-27 Vertex Pharmaceuticals Incorporated Compounds augmenting the activity of antibacterial agents
US20080221163A1 (en) * 2005-01-18 2008-09-11 Jeffrey Alan Dodge Selective Estrogen Receptor Modulators
AU2010292148A1 (en) 2009-09-11 2012-04-12 Vertex Pharmaceuticals Incorporated Compositions of N-benzyl-3-(4-chlorophenyl)-2- [methyl-[2-oxo-2-(3,4,5-trimethoxyphenyl) acetyl]amino]-N- [3-(4-pyridyl)-1-[2-[4-pyridyl)ethy]propyl]propanamide and uses thereof
CN103130631A (zh) * 2011-11-29 2013-06-05 中国人民解放军第二军医大学 1-取代苯亚甲基-2-萘酮类衍生物及制备方法和用途

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5192773A (en) * 1990-07-02 1993-03-09 Vertex Pharmaceuticals, Inc. Immunosuppressive compounds
NZ314207A (en) * 1992-09-28 2000-12-22 Vertex Pharma 1-(2-Oxoacetyl)-piperidine-2-carboxylic acid derivatives as multi drug resistant cancer cell sensitizers
US5387685A (en) * 1993-07-16 1995-02-07 American Cyanamid Co MDR reversal agents

Also Published As

Publication number Publication date
DE69622871T2 (de) 2003-04-10
AU5862096A (en) 1996-11-29
NO975198L (no) 1998-01-19
SK155497A3 (en) 1998-04-08
MX9708830A (es) 1998-03-31
AU705167B2 (en) 1999-05-20
CZ364197A3 (cs) 1998-03-18
CA2219752A1 (en) 1996-11-21
HUP9802679A3 (en) 2000-03-28
HUP9802679A2 (hu) 1999-03-29
DE69622871D1 (de) 2002-09-12
DK0839143T3 (da) 2002-11-18
NO975198D0 (no) 1997-11-12
JPH11505255A (ja) 1999-05-18
ZA963959B (en) 1996-11-25
WO1996036630A1 (en) 1996-11-21
PT839143E (pt) 2002-12-31
CN1184475A (zh) 1998-06-10
BR9608789A (pt) 1999-02-17
PL323490A1 (en) 1998-03-30
IL118269A0 (en) 1996-09-12
US5726184A (en) 1998-03-10
EP0839143B1 (en) 2002-08-07
ATE221881T1 (de) 2002-08-15
KR19990014848A (ko) 1999-02-25
NZ308789A (en) 1999-07-29
EP0839143A1 (en) 1998-05-06

Similar Documents

Publication Publication Date Title
ES2179945T3 (es) Compuestos de tetralina con actividad de resistencia a multiples farmacos.
CO4770978A1 (es) Empleo de epinastina para el tratamiento de dolores
GT199700089A (es) Derivados 6.6 o 6.7 -biciclicos sustituidos que contienen pirido o pirimido.
UY24256A1 (es) Anticuerpos monoclonales de mono especificos para anticuerpos humanos b 7.1 y/o b7.2, formas primatizadas de los mis- mos, composiciones farmaceuticas que los contienen y uso de los mismos como inmunosupresores
GT199900070A (es) Derivados de isotiazol, utiles como agentes anticancerosos.
ES2193245T3 (es) Reactivos estables para la preparacion de radiofarmacos.
PA8442001A1 (es) Derivados de pirimidina biciclica condensada
ES2161290T3 (es) Derivados de quinazolina.
CO5271715A1 (es) 7-aza-indolin-2-onas sustituidas en 4 y su uso como inhibidores de proteiuna quinasa
GT200500007A (es) [1,8]naftiridin-2-onas y compuestos relacionados para el tratamiento de la esquizofrenia.
AR002289A1 (es) Derivados de acetamida, procedimiento para prepararlos, las composiciones farmaceuticas que los contienen y las aplicaciones de dichos compuestos comoansioliticos y en el tratamiento de enfermedades inmuno-inflamatorias.
ECSP034796A (es) DERIVADOS DIHIDRO-BENZO[b][1,4]DIAZEPIN-2-ONA ANTAGONISTAS I MGLUR2
ES2154262T3 (es) Uso de compuestos macrolidos para enfermedades oculares.
PA8508201A1 (es) Derivados de heterociclo-alquilsulfonil pirazolo como agentes anti-inflamatorios/analgesicos
GT199900185A (es) Novedosa pirimidin-4-enamina como fungicida.
MX9307232A (es) Arilcicloalquilaminas n,n-disustituidas, sus sales, medicamentos que contiene estos compuestos y su empleo, asi como procedimientos para su preparacion.
ES2164465T3 (es) Uso de aminometil-cromanos sustituidos para evitar la degeneracion neuronal y para estimular la regeneracion neuronal.
AR008781A1 (es) Compuestos de furano nitrona
AR005102A1 (es) Compuestos derivados de octahidro-pirrolo [1,2-a]-pirazina 2,7-sustituidos, composiciones farmaceuticas y uso de dichos compuestos para la fabricacion deun medicamento.
ES2061811T3 (es) Uso de compuestos de gamma-oxibutenolido conjugados para tratar ulcera.
MX9401295A (es) Fosfonatos sustituidos, los procedimientos para supreparacion y composiciones farmaceuticas que los contienen.
ES2159357T3 (es) Derivados terpenoides (sarcodictinas) utiles como agentes antitumorales.
ES2129893T3 (es) Dinucleosido-5',5'-pirofosfatos.
ES2195158T3 (es) Amidas de alfa-aminoacidos, su preparacion y el uso terapeutico de las mismas.
MX9401172A (es) Derivados fluorados de 4-aminoandrostadienona, procesamiento para su preparacion y composiciones farmaceuticas que los contienen.